CryoPort stock price target raised to $15 from $10 at BTIG

Investing.com - BTIG has raised its price target on CryoPort (NASDAQ:CYRX) to $15.00 from $10.00 while maintaining a Buy rating, citing an improving fundamental outlook for the industry. Currently trading at $8.87, the stock sits below analysts’ consensus target range of $8-$16, with InvestingPro analysis suggesting the company is slightly undervalued.

The firm noted that CryoPort delivered a strong second-quarter revenue beat, with Life Science revenue increasing 21% year-over-year. Revenue from commercially approved products continues to rise rapidly, according to BTIG’s analysis. InvestingPro data shows impressive overall revenue growth of 24.93% over the last twelve months, with a healthy gross profit margin of 45%.

BTIG highlighted several positive industry trends supporting its more optimistic outlook, including accelerating FDA approvals for cell and gene therapy products, steady growth in the number of such products in clinical trials, and the easing of Risk Evaluation and Mitigation Strategy (REMS) requirements for some products.

CryoPort’s gross margin and product revenue growth are showing good improvement, BTIG observed. The company also maintains a strong financial position with over $400 million in cash.

BTIG acknowledged that CryoPort stock has been under pressure for approximately two years, likely due to concerns about the Inflation Reduction Act, tariffs, Most Favored Nation policies, and drug pricing reform risks, but believes the market is "turning the corner."

In other recent news, CryoPort Inc. reported its second-quarter 2025 earnings with impressive results. The company posted earnings per share of $2.05, significantly beating the forecast of -$0.27. Revenue also exceeded expectations, reaching $45.5 million compared to the anticipated $41.74 million, marking a 9.01% increase. Following these strong financial results, KeyBanc upgraded CryoPort’s stock rating to Overweight, noting the company’s 33% revenue growth in commercial cell and gene therapies and substantial growth in its BioStorage and Life Sciences Services segments.

Additionally, Leerink Partners upgraded CryoPort from Market Perform to Outperform, citing the company’s dominant market position and growth potential. The firm raised its price target to $16.00, expressing confidence in CryoPort’s ability to exceed expectations and deliver growth beyond consensus estimates in the coming years. Jefferies also raised its price target on CryoPort to $8.00, maintaining a Hold rating, while highlighting the company’s strong second-quarter performance. These developments reflect a positive outlook from analysts on CryoPort’s market position and financial performance.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.